Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT.
Wieser G, Popp I, Christian Rischke H, Drendel V, Grosu AL, Bartholomä M, Weber WA, Mansi R, Wetterauer U, Schultze-Seemann W, Meyer PT, Jilg CA. Wieser G, et al. Among authors: bartholoma m. Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1463-1472. doi: 10.1007/s00259-017-3702-8. Epub 2017 Apr 18. Eur J Nucl Med Mol Imaging. 2017. PMID: 28417160
Performance of 111In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy.
Mix M, Reichel K, Stoykow C, Bartholomä M, Drendel V, Gourni E, Wetterauer U, Schultze-Seemann W, Meyer PT, Jilg CA. Mix M, et al. Among authors: bartholoma m. Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2062-2070. doi: 10.1007/s00259-018-4094-0. Epub 2018 Jul 30. Eur J Nucl Med Mol Imaging. 2018. PMID: 30062606 Free article.
New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide.
Rosar F, Dewes S, Ries M, Schaefer A, Khreish F, Maus S, Bohnenberger H, Linxweiler J, Bartholomä M, Ohlmann C, Ezziddin S. Rosar F, et al. Among authors: bartholoma m. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):687-694. doi: 10.1007/s00259-019-04674-0. Epub 2020 Jan 3. Eur J Nucl Med Mol Imaging. 2020. PMID: 31901103
Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy.
Rosar F, Hau F, Bartholomä M, Maus S, Stemler T, Linxweiler J, Ezziddin S, Khreish F. Rosar F, et al. Among authors: bartholoma m. Theranostics. 2021 Feb 16;11(9):4050-4060. doi: 10.7150/thno.56211. eCollection 2021. Theranostics. 2021. PMID: 33754047 Free PMC article.
63 results